161 related articles for article (PubMed ID: 38715108)
1. Small protein blockers of human IL-6 receptor alpha inhibit proliferation and migration of cancer cells.
Groza Y; Lacina L; Kuchař M; Rašková Kafková L; Zachová K; Janoušková O; Osička R; Černý J; Petroková H; Mierzwicka JM; Panova N; Kosztyu P; Sloupenská K; Malý J; Škarda J; Raška M; Smetana K; Malý P
Cell Commun Signal; 2024 May; 22(1):261. PubMed ID: 38715108
[TBL] [Abstract][Full Text] [Related]
2. ABD-Derived Protein Blockers of Human IL-17 Receptor A as Non-IgG Alternatives for Modulation of IL-17-Dependent Pro-Inflammatory Axis.
Hlavničková M; Kuchař M; Osička R; Vaňková L; Petroková H; Malý M; Černý J; Arenberger P; Malý P
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30304852
[TBL] [Abstract][Full Text] [Related]
3. Pharmacologic IL-6Rα inhibition in cholangiocarcinoma promotes cancer cell growth and survival.
Kleinegger F; Hofer E; Wodlej C; Golob-Schwarzl N; Birkl-Toeglhofer AM; Stallinger A; Petzold J; Orlova A; Krassnig S; Reihs R; Niedrist T; Mangge H; Park YN; Thalhammer M; Aigelsreiter A; Lax S; Garbers C; Fickert P; Rose-John S; Moriggl R; Rinner B; Haybaeck J
Biochim Biophys Acta Mol Basis Dis; 2019 Feb; 1865(2):308-321. PubMed ID: 30419338
[TBL] [Abstract][Full Text] [Related]
4. Human interleukin-23 receptor antagonists derived from an albumin-binding domain scaffold inhibit IL-23-dependent ex vivo expansion of IL-17-producing T-cells.
Kuchař M; Vaňková L; Petroková H; Cerný J; Osička R; Pelák O; Sípová H; Schneider B; Homola J; Sebo P; Kalina T; Malý P
Proteins; 2014 Jun; 82(6):975-89. PubMed ID: 24549990
[TBL] [Abstract][Full Text] [Related]
5. p19-targeted ABD-derived protein variants inhibit IL-23 binding and exert suppressive control over IL-23-stimulated expansion of primary human IL-17+ T-cells.
Křížová L; Kuchař M; Petroková H; Osička R; Hlavničková M; Pelák O; Černý J; Kalina T; Malý P
Autoimmunity; 2017 Mar; 50(2):102-113. PubMed ID: 28100093
[TBL] [Abstract][Full Text] [Related]
6. Molecular dynamics analysis of the binding of human interleukin-6 with interleukin-6 α-receptor.
Gupta M; Ha K; Agarwal R; Quarles LD; Smith JC
Proteins; 2021 Feb; 89(2):163-173. PubMed ID: 32881084
[TBL] [Abstract][Full Text] [Related]
7. Notch ligand Delta-1 differentially modulates the effects of gp130 activation on interleukin-6 receptor alpha-positive and -negative human hematopoietic progenitors.
Yamamura K; Ohishi K; Katayama N; Kato K; Shibasaki T; Sugimoto Y; Miyata E; Shiku H; Masuya M; Nishioka J; Nobori T; Nishikawa M; Inagaki Y; Hiramatsu H; Nakahata T
Cancer Sci; 2007 Oct; 98(10):1597-603. PubMed ID: 17645774
[TBL] [Abstract][Full Text] [Related]
8. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family.
Mihara M; Kasutani K; Okazaki M; Nakamura A; Kawai S; Sugimoto M; Matsumoto Y; Ohsugi Y
Int Immunopharmacol; 2005 Nov; 5(12):1731-40. PubMed ID: 16102523
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-6 trans-signalling differentially regulates proliferation, migration, adhesion and maspin expression in human prostate cancer cells.
Santer FR; Malinowska K; Culig Z; Cavarretta IT
Endocr Relat Cancer; 2010 Mar; 17(1):241-53. PubMed ID: 19966016
[TBL] [Abstract][Full Text] [Related]
10. Establishment of a novel cell-based assay for screening small molecule antagonists of human interleukin-6 receptor.
He YY; Yan Y; Zhang C; Li PY; Wu P; Du P; Zeng DD; Fang JS; Wang S; Du GH
Acta Pharmacol Sin; 2014 Nov; 35(11):1453-62. PubMed ID: 25345743
[TBL] [Abstract][Full Text] [Related]
11. Blockade of interleukin-6 receptor suppresses the proliferation of H460 lung cancer stem cells.
Yi H; Cho HJ; Cho SM; Jo K; Park JA; Kim NH; Amidon GL; Kim JS; Shin HC
Int J Oncol; 2012 Jul; 41(1):310-6. PubMed ID: 22552503
[TBL] [Abstract][Full Text] [Related]
12. IL-6 trans-signaling in formation and progression of malignant ascites in ovarian cancer.
Lo CW; Chen MW; Hsiao M; Wang S; Chen CA; Hsiao SM; Chang JS; Lai TC; Rose-John S; Kuo ML; Wei LH
Cancer Res; 2011 Jan; 71(2):424-34. PubMed ID: 21123455
[TBL] [Abstract][Full Text] [Related]
13. Antitumor effects of interleukin-6 (IL-6)/interleukin-6 receptor (IL-6R) signaling pathway inhibition in clear cell carcinoma of the ovary.
Yanaihara N; Hirata Y; Yamaguchi N; Noguchi Y; Saito M; Nagata C; Takakura S; Yamada K; Okamoto A
Mol Carcinog; 2016 May; 55(5):832-41. PubMed ID: 25856562
[TBL] [Abstract][Full Text] [Related]
14. Reversal of some viral IL-6 electrostatic properties compared to IL-6 contributes to a loss of alpha receptor component recruitment.
Perret D; Rousseau F; Tran V; Gascan H
Proteins; 2005 Jul; 60(1):14-26. PubMed ID: 15861391
[TBL] [Abstract][Full Text] [Related]
15. IL-6 as a corneal wound healing mediator in an in vitro scratch assay.
Arranz-Valsero I; Soriano-Romaní L; García-Posadas L; López-García A; Diebold Y
Exp Eye Res; 2014 Aug; 125():183-92. PubMed ID: 24971496
[TBL] [Abstract][Full Text] [Related]
16. Soluble interleukin-6 receptor (sIL-6R) makes IL-6R negative T cell line respond to IL-6; it inhibits TNF production.
Igaz P; Horváth A; Horváth B; Szalai C; Pállinger E; Rajnavölgyi E; Tóth S; Rose-John S; Falus A
Immunol Lett; 2000 Mar; 71(3):143-8. PubMed ID: 10722865
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Tyrosine-Phosphorylated STAT3 in Human Breast and Lung Cancer Cells by Manuka Honey is Mediated by Selective Antagonism of the IL-6 Receptor.
Aryappalli P; Shabbiri K; Masad RJ; Al-Marri RH; Haneefa SM; Mohamed YA; Arafat K; Attoub S; Cabral-Marques O; Ramadi KB; Fernandez-Cabezudo MJ; Al-Ramadi BK
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31491838
[TBL] [Abstract][Full Text] [Related]
18. Role of the IL-6 classic- and trans-signaling pathways in corneal sterile inflammation and wound healing.
Ebihara N; Matsuda A; Nakamura S; Matsuda H; Murakami A
Invest Ophthalmol Vis Sci; 2011 Nov; 52(12):8549-57. PubMed ID: 21989726
[TBL] [Abstract][Full Text] [Related]
19. Mesothelin overexpression promotes autocrine IL-6/sIL-6R trans-signaling to stimulate pancreatic cancer cell proliferation.
Bharadwaj U; Marin-Muller C; Li M; Chen C; Yao Q
Carcinogenesis; 2011 Jul; 32(7):1013-24. PubMed ID: 21515913
[TBL] [Abstract][Full Text] [Related]
20. A fusion protein of the gp130 and interleukin-6Ralpha ligand-binding domains acts as a potent interleukin-6 inhibitor.
Ancey C; Küster A; Haan S; Herrmann A; Heinrich PC; Müller-Newen G
J Biol Chem; 2003 May; 278(19):16968-72. PubMed ID: 12646580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
